KH-3

• CAT Number: I042938
• CAS Number: 1215115-03-9
• Molecular Formula: C21H22N2O4S2
• Molecular Weight: 430.54
• Purity: ≥95%
• Synonyms: (E)-3-[5-[(4-tert-butylphenyl)sulfonylamino]-1-benzothiophen-2-yl]-N-hydroxyprop-2-enamide
• InChI: InChI=1S/C21H22N2O4S2/c1-21(2,3)15-4-8-18(9-5-15)29(26,27)23-16-6-10-19-14(12-16)13-17(28-19)7-11-20(24)22-25/h4-13,23,25H,1-3H3,(H,22,24)/b11-7+
• InChIKey: RIYPLPNXICDUCS-YRNVUSSQSA-N
• SMILES: CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=CC3=C(C=C2)SC(=C3)C=CC(=O)NO

KH-3 is a potent RNA-binding protein Hu antigen R (HuR) inhibitor with an IC50 value of 0.35 μM. KH-3 has anti-proliferative activity. KH-3 suppresses breast cancer cell invasion as well as delays the initiation of lung colonies by disrupting HuR-FOXQ1 mRNA interaction[1].
KH-3 (0-100 μM; 48 h; human breast cancer cell lines) blocks HuR function through decrease Bcl-2, Mis2 and XIAP mRNA levels and inhibits breast cancer cells growth in a dose dependent manner[1].
KH-3 (0-10 μM; 0-24 h; MDA-MB-231 and SUM159 cells) inhibits breast cancer cell migration and invasion in a dose dependent manner[1].
KH-3 (0-10 μM; MDA-MB-231 and SUM159 cells) inhibits the interaction between HuR and FOXQ1 mRNA and decreases the amount of HuR protein pulled down by biotinylated AREFOXQ1 RNA oligomer[1].
KH-3 (100 mg/kg; i.p.; three times a week for three weeks; female athymic NCr-nu/nu mice and BALB/c mice) inhibits breast cancer growth and metastasis in vivo[1].

Reference

[1]. Wu X, et, al. Targeting the interaction between RNA-binding protein HuR and FOXQ1 suppresses breast cancer invasion and metastasis. Commun Biol. 2020 Apr 24;3(1):193.
 [Content Brief]